# HUTCHMED (China) Limited American (HCM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.09, market value $2.4 billion.

## Valuation
- **P/E (trailing): 140.9×** (5-yr avg 178.9×, 3-yr avg 178.9×). HUTCHMED (China) Limited American trades at 140.9× trailing earnings, well below its own five-year average of 178.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 54.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.05**. A PEG of 0.05 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4.5×**. Each dollar of revenue is priced at 4.5×.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -3.2%** (5-yr avg -0.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 0.7%**. The inverse of the P/E: 0.7% of the price is earned each year.

## Profitability
- **Operating margin: -7.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 83.3%**. 83.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 36.9%**. 36.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: -2.5%**. Return on all capital, debt included, is -2.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 26.1%**. Each dollar of assets produces 26.1% of profit.

## Growth
- **Revenue growth (1 yr): -13.0%** (3-yr 8.8%/yr, 5-yr 19.2%/yr). Revenue fell 13.0% over the last year, against 19.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 1200.0%**. Earnings per share rose 1200.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.08**. Debt is 0.08 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. HUTCHMED (China) Limited American holds more cash than debt.
- **Altman Z-score: 4.16**. A Z-score of 4.16 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. HUTCHMED (China) Limited American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover HUTCHMED (China) Limited American; the consensus is buy, with an average price target of $20.99 (+49% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -5.1%** (YTD 5.7%, 3-mo 29.6%). The shares are down 5.1% over twelve months including dividends.
- **From 52-week high: -23.0%** (44.2% above the low). Trading 23% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 74**. An RSI of 74 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.67** (volatility 39%). Beta of 0.67 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HCM · Page: https://foliofundamentals.com/stocks/hcm

Not investment advice.